Scott Henry

Ken Mestemacher

Max Jacobs

Mitchell Kapoor

Raghuram Selvaraju

- InMed Pharmaceuticals Inc. reported a **net loss of $8.2 million** for the fiscal year ended June 30, 2025, an increase from $7.7 million in the prior year.  **[1728328_0001213900-25-090715_ea025845801ex99-1_inmed.htm:1]** 
- The company held **$11.1 million** in cash, cash equivalents, and short-term investments as of June 30, 2025, which is projected to fund operations into the **fourth quarter of calendar year 2026**.  **[1728328_0001213900-25-090715_ea025845801ex99-1_inmed.htm:0]** **[1728328_0001213900-25-090715_ea025845801ex99-1_inmed.htm:2]** 
- The BayMedica commercial segment recorded **$4.9 million in sales** for fiscal year 2025, representing an **8% increase** compared to the previous year.  **[1728328_0001213900-25-090715_ea025845801ex99-1_inmed.htm:1]** 
- Significant progress was made in the **INM-901 program** for Alzheimer's disease, with preclinical studies showing reduced neuroinflammation and improved cognitive function, and plans to advance towards an IND submission in fiscal 2026.  **[1728328_0001213900-25-090715_ea025845801ex99-1_inmed.htm:0]** **[1728328_0001213900-25-090715_ea025845801ex99-1_inmed.htm:1]**

InMed Pharmaceuticals Reports FY2025 Financial Results and Business Update

- InMed Pharmaceuticals is advancing its drug pipeline, with **INM-901 for Alzheimer's** and **INM-089 for dry age-related macular degeneration** both in preclinical phases and planning pre-IND meetings with the FDA next year.  **[1728328_2147460_1]** **[1728328_2147460_4]** 
- Preclinical data for INM-901 demonstrated reduced amyloid beta load, neuroinflammation, increased neuroprotection, and improved cognitive functions in a mouse model.  **[1728328_2147460_2]** **[1728328_2147460_3]** 
- The company is seeking partnerships for **INM-755**, a CBN cream that completed a Phase 2 study for epidermolysis bullosa, showing strong anti-itch activity, to advance it to Phase 3.  **[1728328_2147460_4]** **[1728328_2147460_5]** 
- InMed's commercial entity, BayMedica, generates approximately **$5 million per year** from manufacturing rare cannabinoids for the health and wellness market and is profitable.  **[1728328_2147460_5]** 
- The company reported an estimated cash balance of **$9.2 million** at the end of June, providing a cash runway into the **fourth quarter of calendar 2026**.  **[1728328_2147460_6]**

InMed Pharmaceuticals (INM)